Anti–PD-1 Immunotherapy Shows Activity in Relapsed Lymphoma Patients Cancer Network The combination of rituximab (Rituxan) and the novel immunotherapy pidilizumab (CT-011) is both active and well tolerated in follicular lymphoma patients, according to results of a phase II trial presented by Jason R. Westin, MD, of the MD Anderson ... |
